false 0001627223 0001627223 2019-10-03 2019-10-03

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

October 3, 2019

Date of Report (Date of Earliest Event Reported)

The Chemours Company

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware

 

001-36794

 

46-4845564

(State or Other Jurisdiction

 

(Commission

 

(I.R.S. Employer

Of Incorporation)

 

File Number)

 

Identification No.)

 

1007 Market Street

Wilmington, Delaware, 19801

(Address of principal executive offices)

 

Registrant’s telephone number, including area code: (302) 773-1000

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

 

Trading Symbol(s)

 

Name of Exchange on Which Registered

Common Stock ($.01 par value)

 

CC

 

New York Stock Exchange

 

 

 

 

 


 

Item 5.02             Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

 

On October 3, 2019, The Chemours Company (the “Company”) announced the separation from service of Paul Kirsch, President – Fluoroproducts.  In connection with his departure, Mr. Kirsch and the Company entered into a separation agreement and release (the “Agreement”).

 

Pursuant to the Agreement, Mr. Kirsch’s employment with the Company will continue through October 31, 2019.  Mr. Kirsch will receive benefits consistent with the Company’s severance plans and policies, including notice and separation payments in the aggregate amount of $63,462 and a prorated annual incentive program (AIP) award at target in the amount of $343,750.  Also consistent with the Company’s severance plans and policies, certain vested stock options held by Mr. Kirsch with an approximate market value of $171,176 will continue to be exercisable for a period of one year.  In addition to these benefits, in connection with ongoing non-competition obligations, Mr. Kirsch will be entitled to a payment in the amount of $595,833.  Mr. Kirsch will also have ongoing confidentiality and non-solicitation obligations under the Agreement.

 

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

THE CHEMOURS COMPANY

 

By:

 

/s/ Sameer Ralhan

 

 

Sameer Ralhan

 

 

Senior Vice President, Chief Financial

 

 

Officer and Treasurer

 

Date:

 

October 3, 2019

 

 

 

Chemours (NYSE:CC)
Historical Stock Chart
From May 2020 to Jun 2020 Click Here for more Chemours Charts.
Chemours (NYSE:CC)
Historical Stock Chart
From Jun 2019 to Jun 2020 Click Here for more Chemours Charts.